SOMERSET, N.J., May 17, 2018 /PRNewswire-PRWeb/ -- Catalent Pharma Solutions, the leading global provider of advanced
The latest expansion includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, providing the site with an additional 3,600 square feet of storage, as well as additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations. A new sampling room has been installed, as well as a new emergency generator to ensure the security and integrity of samples in storage.
"Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years," commented Kevin Economos, General Manager of Clinical Supply Services at the site. "These latest expansions are critical enablers to our customers' continued growth, that reinforce our comprehensive global network, and enhance Catalent's role as a market leader in the clinical supply industry."
Catalent's 450,000-square feet Kansas City facility provides a range of fully integrated support services, from development and analytical support through to packaging and distribution. The expansions at Kansas City follow the recent announcements of new capabilities and capacity at two of Catalent's other clinical supply facilities in Philadelphia and Singapore.
With sites in the U.S., U.K., Germany, Singapore, Japan and China, and an extended network of over 50 depots, Catalent's clinical supply services team has the capability and expertise to handle a broad range of international compliance and distribution requirements, and so help to expedite clinical trials by ensuring customers are reliably supplied where and when needed around the globe.
For further information on Catalent's Clinical Supply Services business visit catalent.com/clinical.
About Catalent Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
SOURCE Catalent, Inc.
Subscribe to our Free Newsletters!
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ...
Patisiran injection, recently approved by FDA to treat polyneuropathy, a disease that causes ...
Dysgraphia or disorder of written expression is a childhood learning disorder marked by poor ...View All